BrYet Receives Australian Phase 1/2 Approval and Submits IND to the US for ML-016, a Novel Cancer Drug Targeting Phenotypes
A Paradigm Shift in Overcoming Genetic Instability
The greatest challenge in cancer treatment is the development of drug resistance and recurrence due to the genetic instability of cancer cells. Unlike existing targeted therapies that target only specific gene mutations and are limited by the development of resistance, the privately-held biotech company, BrYet US, Inc., has adopted a strategy of directly targeting the common functional and biological characteristics (phenotype) of cancer cells. This innovative approach is expected to provide consistent therapeutic effects even in metastatic cancer environments where gene mutations constantly occur. The drug is designed to block the transport mechanisms that cancer cells must maintain for survival, thereby securing a therapeutic pathway ahead of the evolution of cancer.
Precision Delivery Based on the Si-Plateloid™ Platform Technology
BrYet's core platform technology, Si-Plateloid™, is a silicon microstructural material shaped like platelets, which selectively targets the vascular endothelium of the tumor microenvironment. ML-016, the lead pipeline product based on this platform, has a unique conjugate structure consisting of an amino acid polymer and doxorubicin, a chemotherapeutic agent. When the drug reaches near the cancer cells, it forms exosome-like vesicles called exosomoids, which selectively enter the cancer cells. Subsequently, the drug is selectively released only in the acidic environment of late-stage endosomes and lysosomes within the cells, minimizing toxicity and maximizing therapeutic efficacy.
Global Clinical Entry and Broad Regulatory Approval
BrYet has received approval from the Australian regulatory agency for the first-in-human Phase 1/2 clinical trial of ML-016 and has subsequently submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA), accelerating its global clinical expansion. In particular, the clinical trial approved in Australia has obtained a groundbreaking design that targets all primary and metastatic solid tumors, including those that have metastasized to the liver and lungs, without being limited to specific molecular subtypes. This breaks away from the conventional clinical trial design of existing targeted therapies that act only on specific mutations, suggesting that the Molecular Transport Phenotype Targeting (MTPT) has universal potential. This demonstrates that regulatory authorities are positively evaluating the platform value of this innovative approach.
Market Expansion and Competitive Landscape with Existing Therapies
The global market for lung cancer treatments is approximately $35 billion (USD), and the market for liver metastasis treatments is close to $1.7 billion, making the commercial potential of ML-016, which targets these markets, very large. The current standard of care for metastatic cancer is immune checkpoint inhibitors such as Keytruda or specific targeted therapies, but there is a lack of alternatives for patients who still develop resistance at a high rate. ML-016, which maintains the potent anti-cancer efficacy of doxorubicin, a chemotherapeutic agent, while significantly reducing systemic toxicity through the targeting of cancer cell transport phenotypes, can provide a new standard treatment option for patients who have failed existing therapies. If excellent safety and efficacy are demonstrated in future clinical data, it will become a game-changer that will shake up the next-generation cancer drug market beyond the limitations of single targets.
BrYet US, Inc., a privately-held biotech company, has entered the global clinical stage with its lead pipeline product, ML-016, after receiving Australian Phase 1/2 approval and submitting an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA). This novel drug applies a new mechanism called Molecular Transport Phenotype Targeting (MTPT) to address the issue of drug resistance caused by the single-gene targeting limitations of existing immune checkpoint inhibitors such as Keytruda and other targeted therapies. Targeting both the global lung cancer market, valued at approximately $35 billion, and the liver metastasis treatment market, it has high commercial potential due to its ability to be applied to a broad patient population regardless of specific mutations. From a researcher's perspective, securing safety and efficacy data for the Si-Plateloid™ platform, which selectively delivers doxorubicin to late-stage endosomes and lysosomes within cancer cells, will be a key short-term metric. In the medium to long term, if this platform is successful, it is expected that the paradigm of existing cancer research, which has been dependent on gene mutations, will shift to targeting physical transport characteristics, and this will have a significant impact on the entire oncology R&D field.